OncoMatch/Clinical Trials/NCT04513639
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Is NCT04513639 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Early treatment of relapse with carfilzomib, dexamethasone, daratumumab and Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab for multiple myeloma.
Treatment: Early treatment of relapse with carfilzomib, dexamethasone, daratumumab · Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab — The REMNANT study will evaluate whether treating minimal residual disease (MRD) relapse after first line treatment prolongs progression free survival and overall survival for myeloma patients versus treating relapse after first line treatment at progressive disease. To establish a homogenous group of MRD negative patients after first line treatment including autologous stem cell transplantation, patients are enrolled at diagnosis and treated with Norwegian standard of care first line treatment. MRD negative patients will move on to the randomized part.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: high-dose therapy and ASCT eligible
eligible for high-dose therapy and ASCT
Must have received: 1.L treatment in part 1 of the study
Has received 1.L treatment in part 1 of the study.
Cannot have received: induction treatment
Exception: no more than one cycle
Received more than one cycle of induction treatment for multiple myeloma.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify